Holen Sie sich die Stockscreener-App
3.43
7.19%
0.23
Vorhandelsmarkt:
3.39
-0.04
-1.17%
Schlusskurs vom Vortag:
$3.20
Offen:
$3.22
24-Stunden-Volumen:
227.01K
Relative Volume:
0.34
Marktkapitalisierung:
$28.73M
Einnahmen:
$2.38M
Nettoeinkommen (Verlust:
$-12.40M
KGV:
-0.5307
EPS:
-6.4626
Netto-Cashflow:
$-18.68M
1W Leistung:
+15.10%
1M Leistung:
+19.93%
6M Leistung:
-69.91%
1J Leistung:
-51.70%
1-Tages-Spanne:
$3.10
$3.44
1-Wochen-Bereich:
$2.73
$3.44
52-Wochen-Spanne:
$2.0223
$22.20
Femasys Inc Stock (FEMY) Company Profile
Firmenname
Femasys Inc
Sektor
Telefon
770-500-3910
Adresse
3950 JOHNS CREEK COURT, SUWANEE
Compare FEMY vs ISRG, BDX, ALC, RMD, MDLN
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
FEMY
Femasys Inc
|
3.43 | 22.86M | 2.38M | -12.40M | -18.68M | -6.4626 |
ISRG
Intuitive Surgical Inc
|
376.86 | 132.30B | 11.03B | 3.16B | 3.22B | 8.7251 |
BDX
Becton Dickinson Co
|
188.11 | 51.11B | 21.37B | 1.41B | 3.07B | 3.9437 |
ALC
Alcon Inc
|
72.06 | 35.25B | 10.63B | 819.00M | 1.59B | 1.6577 |
RMD
Resmed Inc
|
240.10 | 32.95B | 5.54B | 1.52B | 1.74B | 10.37 |
MDLN
Medline Inc
|
35.03 | 28.58B | 29.14B | 1.07B | 1.05B | 1.1956 |
Femasys Inc Stock (FEMY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-20 | Eingeleitet | Laidlaw | Buy |
Femasys Inc Aktie (FEMY) Neueste Nachrichten
Femasys (FEMY): Moves 0.74% Higher to $2.73 for the Current Session; the Session Ends Within the Reported Technical Boundaries in Latest TradingVolatility Smirk - vinanet.vn
Biotech Femasys (NASDAQ: FEMY) raises $30M in private round - Stock Titan
Femasys Secures FDA Pathway for Non-Surgical Contraceptive - Sahm
Femasys Jumps as FDA Clears Modular Review Path for Non-Surgical Birth Control - finance.biggo.com
Why Is Femasys Stock Soaring Today?Femasys (NASDAQ:FEMY) - Benzinga
FEMY Stock Rallies On Key Regulatory Milestone For Investigational Birth Control Technology – Retail Sees 500% Upside Potential - TradingView
Femasys receives FDA approval for modular PMA pathway for FemBloc By Investing.com - Investing.com Nigeria
Femasys (FEMY) Results Versus Estimates: EPS Beats Its Estimate in the Latest Reading; Latest Reaction: Shares Move 24.32% Up for the Current SessionLow Growth Earnings - Vinanet
Femasys Secures FDA Approval for Modular PMA Pathway for FemBloc - Yahoo Finance
FDA approves a modular review path for Femasys’ permanent birth control - Stock Titan
Femasys receives FDA approval for modular PMA pathway for FemBloc - Investing.com
Femasys Inc. Announces FDA Approval of Modular PMA Pathway for FemBloc in the U.S. - Quiver Quantitative
Femasys Announces FDA Approval of Modular PMA Submission Approach for FemBloc® - Caledonian Record
Femasys Announces FDA Approval Of Modular Pma Submission Approach For Fembloc - TradingView
Femasys secures $30 million to advance fertility portfolio - The Pharma Letter
Nantahala's $12M deal brings board influence at Femasys (NASDAQ: FEMY) - Stock Titan
FEMY Q1 2026 Earnings: Loss Beat Estimates, Stock Slips 1.31%Earnings Turnaround - vinanet.vn
Femasys earnings missed by $0.20, revenue fell short of estimates - Investing.com Canada
Maxim Group Maintains Femasys(FEMY.US) With Buy Rating, Cuts Target Price to $10 - Moomoo
Femasys 2Q Loss/Shr $1.33 >FEMY - Moomoo
Femasys Stock Price Forecast. Should You Buy FEMY? - StockInvest.us
Femasys Q2 EPS $(1.08) beats estimate; sales rise 85% - scanx.trade
Femasys (NASDAQ: FEMY) cuts net loss and secures $30M private funding - Stock Titan
Femasys reports $331,827 Q2 revenue, $4.47M net loss and $30M financing to support U.S. commercial push - TradingView
Femasys Reports $331,827 Q2 Revenue and $4.47 Million Net Loss - Quiver Quantitative
Femasys Inc. (NASDAQ: FEMY) narrows first-half loss, completes $30M financing - Stock Titan
Femasys Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Femasys (FEMY) gains Rosalind-linked holder with potential 9.99% equity stake - Stock Titan
FEMY Q1 2026 Earnings: Narrower Loss Beats Estimates as Stock Slips 2.55%Earnings Decline Risk - vinanet.vn
FEMY Q1 2026 Earnings: Narrower-Than-Expected Loss of -$1.20 Per Share, Yet Shares Dip 2.34%ROIC Trend Report - Vinanet
Femasys Strengthens and Extends Global Patent Protection for FemBloc with First Issued Blended Polymer Patents - marketscreener.com
Femasys Inc. (FEMY) Q1 2026 Earnings: Narrower-Than-Expected Loss of -$1.20 Per Share Beats Estimates by 34.64% - dars.gov.et
Femasys receives patents for FemBloc birth control polymer By Investing.com - Investing.com South Africa
Femasys receives patents for FemBloc birth control polymer - Investing.com
Femasys Secures New U.S. and International Patents for FemBloc Blended Polymer, Expanding Global IP Protection - Quiver Quantitative
Femasys Strengthens and Extends Global Patent Protection for FemBloc® with First Issued Blended Polymer Patents - Yahoo Finance
Femasys COO John Canning buys $14,000 in FEMY stock By Investing.com - Investing.com Australia
Femasys COO John Canning buys $14,000 in FEMY stock - Investing.com India
Femasys chief clinical-medical affairs Mifek buys $10,000 stock By Investing.com - Investing.com Australia
Femasys CFO Dov Elefant buys $50,000 in company stock By Investing.com - Investing.com South Africa
Femasys CTO Jeremy Sipos buys $10,000 in common stock - Investing.com India
Femasys CEO Kathy Lee-Sepsick buys $50,000 in FEMY stock By Investing.com - Investing.com Australia
Femasys CFO Dov Elefant buys $50,000 in company stock - Investing.com
Femasys chief clinical-medical affairs Mifek buys $10,000 stock - Investing.com
Femasys CTO Jeremy Sipos buys $10,000 in common stock By Investing.com - Investing.com Australia
Femasys CEO Kathy Lee-Sepsick buys $50,000 in FEMY stock - Investing.com
Form 8K Femasys Inc For: 11 August By Investing.com - Investing.com South Africa
Femasys completes $30 million private placement financing - TipRanks
Finanzdaten der Femasys Inc-Aktie (FEMY)
Umsatz
Nettogewinn
Free Cashflow
ENV
Femasys Inc-Aktie (FEMY) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Sipos Jeremy Alexander | Chief Technology Officer |
Aug 07 '26 |
Buy |
3.20 |
3,125 |
10,000 |
3,125 |
| Canning John Charles | Chief Operating Officer |
Aug 07 '26 |
Buy |
3.20 |
4,375 |
14,000 |
4,375 |
| Elefant Dov | Chief Financial Officer |
Aug 07 '26 |
Buy |
3.20 |
15,625 |
50,000 |
15,625 |
| Lee-Sepsick Kathy | Chief Executive Officer |
Aug 07 '26 |
Buy |
3.20 |
15,625 |
50,000 |
15,625 |
1.40%
0.50%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):